References

References 1-50

1. Siegel RL, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33.
2. Miller KD, et al. Cancer Treatment and Survivorship Statistics, 2022. CA Cancer J Clin 2022;0:1-28.
3. Kratzer TB, et al. Progress against cancer mortality 50 years after passage of the National Cancer Act. JAMA Oncol 2022;8:156-9.
4. Siegel RL, et al. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30.
5. National Cancer Institute. Surveillance, Epidemiology, and End Results program explorer. Accessed: June 30, 2022. Available from: https://seer.cancer.gov/statistics-network/explorer/application.html
6. Nayak RK, et al. Public-sector contributions to novel biologic drugs. JAMA Intern Med 2021;181:1522-5.
7. Galkina Cleary E, et al. Contribution of NIH funding to new drug approvals 2010-2016. Proc Natl Acad Sci U S A 2018;115:2329-34.
8. American Association for Cancer Research. AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care. Accessed: June 30, 2022. Available from: https://www.aacr.org/professionals/research/aacr-covid-19-and-cancer-report-2022/
9. Dieci MV, et al. Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study. Eur J Cancer 2022;167:81-91.
10. National Cancer Institute. NCI COVID-19 in Cancer Patients Study (NCCAPS). Accessed: Nov 27, 2021. Available from: https://www.cancer.gov/research/key-initiatives/covid-19/coronavirus-research-initiatives/nccaps
11. Gaddam S, et al. Incidence of pancreatic cancer by age and sex in the US from 2000 to 2018. JAMA 2022;327:1402-3.
12. Cancer health disparities definitions and examples. Accessed: April 22, 2022. Available from: https://www.cancer.gov/about-nci/organization/crchd/about-health-disparities/definitions
13. American Association for Cancer Research. AACR Cancer Disparities Progress Report 2022. Accessed: June 30, 2022. Available from: https://cancerprogressreport.aacr.org/disparities/
14. Lawrence WR, et al. Trends in cancer mortality among black individuals in the US from 1999 to 2019. JAMA Oncol 2022.
15. Heslin KC, et al. Sexual orientation differences in access to care and health status, behaviors, and beliefs: Findings from the National Health and Nutrition Examination Survey, National Survey of Family Growth, and National Health Interview Survey. Natl Health Stat Report 2022:1-16.
16. Moon PK, et al. Head and neck cancer stage at presentation and survival outcomes among Native Hawaiian and Other Pacific Islander patients compared with Asian and White patients. JAMA Otolaryngol Head Neck Surg 2022;148:636-45.
17. Centers for Disease Control and Prevention. An update on cancer deaths in the United States. Accessed: July 15, 2022. Available from: https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths/index.htm
18. Sung H, et al. Subsequent primary cancer risk among five-year survivors of adolescent and young adult cancers. J Natl Cancer Inst 2022.
19. Gupta A, et al. Association of area-level socioeconomic status and non-small cell lung cancer stage by race/ethnicity and health care-level factors: Analysis of the National Cancer Database. Cancer 2022;128:3099-108.
20. Elizabeth Read-Connole, et al. Basic/Translational research on Health Disparities in HIV/AIDS and cancer (Clinical trial optional). 2022.
21. American Association for Cancer Research. AACR Cancer Progress Report 2021. Accessed: Dec 19, 2021. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2021/10/AACR_CPR_2021.pdf
22. Shiels MS, et al. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS 2017;12:6-11.
23. Shiels MS, et al. Projected cancer incidence rates and burden of incident cancer cases in hiv-infected adults in the United States through 2030. Ann Intern Med 2018;168:866-73.
24. Luo Q, et al. Years of life lost to cancer among the United States HIV population, 2006-2015. AIDS 2022;36:1279-86.
25. National Cancer Institute. Division of Cancer Epidemiology & Genetics. HIV/AIDS cancer match study. Accessed: July 28, 2022. Available from: https://hivmatch.cancer.gov/
26. International Agency for Research on Cancer. Global Cancer Observatory. Accessed: July 15, 2022. Available from: https://gco.iarc.fr/today
27. U.S. Department of Health and Human Services. Administration for Community Living. 2020 Profile of Older Americans. Accessed: Jul 6, 2022. Available from: https://acl.gov/sites/default/files/Aging%20and%20Disability%20in%20America/2020ProfileOlderAmericans.Final_.pdf
28. Sinicrope FA. Increasing incidence of early-onset colorectal cancer. N Engl J Med 2022;386:1547-58.
29. Calip GS, et al. Colorectal cancer incidence among adults younger than 50 years-understanding findings from observational studies of lower gastrointestinal endoscopy. JAMA Oncol 2022;8:981-3.
30. Kocarnik JM, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the global burden of disease study 2019. JAMA Oncol 2022;8:420-44.
31. The ASCO Post Staff. War is hell. It’s also a public health disaster, especially for people with cancer. Accessed: July 6, 2022. Available from: https://ascopost.com/issues/march-25-2022/war-is-hell-it-s-also-a-public-health-disaster-especially-for-people-with-cancer/
32. United Nations. Ageing. Accessed: July 6, 2022. Available from: https://www.un.org/en/global-issues/ageing
33. Pramesh CS, et al. Priorities for cancer research in low- and middle-income countries: a global perspective. Nat Med 2022;28:649-57.
34. GBD Respiratory Tract Cancers Collaborators. Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Respir Med 2021;9:1030-49.
35. Coles CE, et al. The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge. Lancet 2022;399:1101-3.
36. GBD Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol 2022;7:627-47.
37. GBD Adolescent Young Adult Cancer Collaborators. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Oncol 2022;23:27-52.
38. Yabroff KR, et al. Annual Report to the Nation on the Status of Cancer, part 2: Patient economic burden associated with cancer care. J Natl Cancer Inst 2021;113:1670-82.
39. Zaorsky NG, et al. Medical service use and charges for cancer care in 2018 for privately insured patients younger than 65 years in the US. JAMA Netw Open 2021;4:e2127784.
40. Nguyen B, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell 2022;185:563-75 e11.
41. Yang D, et al. Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell 2022;185:1905-23 e25.
42. Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov 2022;12:31-46.
43. Collins FS, et al. Basic science: Bedrock of progress. Science 2016;351:1405.
44. Lin CP, et al. Noncoding RNAs in cancer development. Annu Rev Canc Biol 2017;1:163-84.
45. Segal E, et al. From DNA sequence to transcriptional behaviour: a quantitative approach. Nat Rev Genet 2009;10:443-56.
46. Drews RM, et al. A pan-cancer compendium of chromosomal instability. Nature 2022;606:976-83.
47. Huang KL, et al. Pathogenic germline variants in 10,389 adult cancers. Cell 2018;173:355-70 e14.
48. Zeng C, et al. Association of pathogenic variants in hereditary cancer genes with multiple diseases. JAMA Oncol 2022;8:835-44.
49. Momozawa Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol 2022;8:871-8.
50. Arteaga CL, et al. AACR Cancer Progress Report 2014. Clin Cancer Res 2014;20:S1-S112.

References 51-100

51. Hehir-Kwa JY, et al. Improved gene fusion detection in childhood cancer diagnostics using RNA sequencing. JCO Precis Oncol 2022;6:e2000504.
52. Lee JK, et al. Characterization of non-small-cell lung cancers with MET exon 14 skipping alterations detected in tissue or liquid: Clinicogenomics and real-world treatment patterns. JCO Precis Oncol 2021;5:1354-76.
53. Kim EK, et al. Molecular diagnostic assays and clinicopathologic implications of MET exon 14 skipping mutation in non-small-cell lung cancer. Clin Lung Cancer 2019;20:e123-e32.
54. Clark DJ, et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell 2019;179:964-83 e31.
55. Rodriguez H, et al. The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Cell. Volume 184: Elsevier Inc.; 2021. p 1661-70.
56. Lu Y, et al. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer 2020;19:79.
57. Grishin D, et al. Allelic imbalance of chromatin accessibility in cancer identifies candidate causal risk variants and their mechanisms. Nat Genet 2022;54:837-49.
58. Morales Berstein F, et al. Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study. Elife 2022;11.
59. Sehl ME, et al. The acute effects of adjuvant radiation and chemotherapy on peripheral blood epigenetic age in early stage breast cancer patients. NPJ Breast Cancer 2020;6:23.
60. Megyesfalvi Z, et al. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. J Pathol 2022;257:674-86.
61. Strobl MAR, et al. Spatial structure impacts adaptive therapy by shaping intra-tumoral competition. Commun Med (Lond) 2022;2:46.
62. Secker GA, et al. Regulation of VEGFR signalling in lymphatic vascular development and disease: An update. Int J Mol Sci 2021;22:7760.
63. Dieterich LC, et al. Tumor lymphangiogenesis and new drug development. Adv Drug Deliv Rev 2016;99:148-60.
64. Wang C, et al. Advances in drugs targeting lymphangiogenesis for preventing tumor progression and metastasis. Front Oncol 2021;11:783309.
65. Sun X, et al. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. Nature 2021;599:673-8.
66. Pruis MA, et al. Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing. Br J Cancer 2022.
67. Kornauth C, et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov 2022;12:372-87.
68. Hoes LR, et al. Patients with rare cancers in the Drug Rediscovery Protocol (DRUP) benefit from genomics-guided treatment. Clin Cancer Res 2022;28:1402-11.
69. Gajic ZZ, et al. Recurrent somatic mutations as predictors of immunotherapy response. Nat Commun 2022;13:3938.
70. Berlanga P, et al. The European MAPPYACTS trial: Precision medicine program in pediatric and adolescent patients with recurrent malignancies. Cancer Discov 2022;12:1266-81.
71. Church AJ, et al. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med 2022.
72. Sheinson DM, et al. Trends in use of next-generation sequencing in patients with solid tumors by race and ethnicity after implementation of the medicare national coverage determination. JAMA Netw Open 2021;4:e2138219.
73. Ademuyiwa FO, et al. Genetic counseling and testing in African American patients with breast cancer: A nationwide survey of us breast oncologists. J Clin Oncol 2021;39:4020-8.
74. Kehl KL, et al. Race, poverty, and initial implementation of precision medicine for lung cancer. J Natl Cancer Inst 2019;111:431-4.
75. Palazzo LL, et al. Disparities and trends in genetic testing and erlotinib treatment among metastatic non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2019;28:926-34.
76. Quinn R, et al. Impact of precision medicine on clinical outcomes: A single-institution retrospective study. Front Oncol 2021;11:659113.
77. Brito RA, et al. Total cost of lung cancer care associated with broad panel versus narrow panel sequencing. Journal of Clinical Oncology 2020;38:7077-.
78. Islami F, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin 2018;68:31-54.
79. Brennan P, et al. Identifying novel causes of cancers to enhance cancer prevention: New strategies are needed. J Natl Cancer Inst 2022;114:353-60.
80. Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). Accessed: July 16, 2022. Available from: https://www.cdc.gov/chronicdisease/about/index.htm
81. Islami F, et al. Annual Report to the Nation on the Status of Cancer, Part 1: National cancer statistics. JNCI: Journal of the National Cancer Institute 2021;113:1648-69.
82. Vaz M, et al. Chronic cigarette smoke-induced epigenomic changes precede sensitization of bronchial epithelial cells to single-step transformation by KRAS mutations. Cancer Cell 2017;32:360-76 e6.
83. American Lung Association. State of the Air 2022. Accessed: July 13, 2022. Available from: https://www.lung.org/research/sota
84. Thomson B, et al. Association of smoking initiation and cessation across the life course and cancer mortality: Prospective study of 410000 US adults. JAMA Oncol 2021;7:1901-3.
85. Centers for Disease Control and Prevention. Smoking Cessation: A Report of the Surgeon General. Accessed: Available from: https://www.hhs.gov/sites/default/files/2020-cessation-sgr-full-report.pdf
86. Sengupta R, et al. AACR Cancer Progress Report 2020: Turning science into lifesaving care. Clin Cancer Res 2020;26:5055.
87. Cornelius ME, et al. Tobacco Product Use Among Adults – United States, 2020. MMWR Morb Mortal Wkly Rep 2022;71:397-405.
88. Centers for Disease Control and Prevention. The health consequences of smoking-50 years of progress: A report of the Surgeon General. Accessed: July 6, 2022. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24455788
89. Tsai J, et al. Exposure to secondhand smoke among nonsmokers – United States, 1988-2014. MMWR Morb Mortal Wkly Rep 2018;67:1342-6.
90. Gentzke AS, et al. Tobacco product use and associated factors among middle and high school students – National Youth Tobacco Survey, United States, 2021. MMWR Surveill Summ 2022;71:1-29.
91. Tam J, et al. Estimated prevalence of smoking and smoking-attributable mortality associated with graphic health warnings on cigarette packages in the US from 2022 to 2100. JAMA Health Forum 2021;2.
92. Chaloupka FJ, et al. Tobacco taxes as a tobacco control strategy. Tob Control 2012;21:172-80.
93. Christensen CH, et al. Association of cigarette, cigar, and pipe use with mortality risk in the US population. JAMA Intern Med 2018;178:469-76.
94. National Academy of Sciences. Public health consequences of e-cigarettes. Accessed: July 6, 2022. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29894118
95. Prochaska JJ, et al. Nicotine delivery and cigarette equivalents from vaping a JUULpod. Tob Control 2022;31:e88-e93.
96. Goriounova NA, et al. Short- and long-term consequences of nicotine exposure during adolescence for prefrontal cortex neuronal network function. Cold Spring Harb Perspect Med 2012;2:a012120.
97. Goniewicz ML, et al. Comparison of nicotine and toxicant exposure in users of electronic cigarettes and combustible cigarettes. JAMA Netw Open 2018;1:e185937.
98. Yu V, et al. Electronic cigarettes induce DNA strand breaks and cell death independently of nicotine in cell lines. Oral Oncol 2016;52:58-65.
99. Muthumalage T, et al. E-cigarette flavored pods induce inflammation, epithelial barrier dysfunction, and DNA damage in lung epithelial cells and monocytes. Sci Rep 2019;9:19035.
100. Tehrani MW, et al. Characterizing the chemical landscape in commercial e-cigarette liquids and aerosols by liquid chromatography-high-resolution mass spectrometry. Chem Res Toxicol 2021;34:2216-26.

References 101-150

101. Park-Lee E, et al. Notes from the field: E-cigarette use among middle and high school students – National Youth Tobacco Survey, United States, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1387-9.
102. Sengupta R, et al. AACR Cancer Disparities Progress Report 2020: Achieving the bold vision of health equity for racial and ethnic minorities and other underserved populations. Cancer Epidemiol Biomarkers Prev 2020;29:1843.
103. Pierce JP, et al. Incidence of cigarette smoking relapse among individuals who switched to e-cigarettes or other tobacco products. JAMA Netw Open 2021;4:e2128810.
104. Friedman AS, et al. Associations of flavored e-cigarette uptake with subsequent smoking initiation and cessation. JAMA Netw Open 2020;3:e203826.
105. Xie W, et al. Association of electronic cigarette use with incident respiratory conditions among US adults from 2013 to 2018. JAMA Netw Open 2020;3:e2020816.
106. Xie W, et al. Association of electronic cigarette use with respiratory symptom development among U.S. young adults. Am J Respir Crit Care Med 2022;205:1320-9.
107. Caporale A, et al. Acute effects of electronic cigarette aerosol inhalation on vascular function detected at quantitative MRI. Radiology 2019;293:97-106.
108. Moshensky A, et al. Effects of mango and mint pod-based e-cigarette aerosol inhalation on inflammatory states of the brain, lung, heart, and colon in mice. Elife 2022;11.
109. Kelesidis T, et al. Association of 1 vaping session with cellular oxidative stress in otherwise healthy young people with no history of smoking or vaping: A randomized clinical crossover trial. JAMA Pediatr 2021;175:1174-6.
110. Bjurlin MA, et al. Carcinogen biomarkers in the urine of electronic cigarette users and implications for the development of bladder cancer: A systematic review. Eur Urol Oncol 2021;4:766-83.
111. Choi BM, et al. The decline in e-cigarette use among youth in the United States-an encouraging trend but an ongoing public health challenge. JAMA Netw Open 2021;4:e2112464.
112. New York Times. Youth vaping declined sharply for second year, new data show. Accessed: July 28, 2022. Available from: https://www.nytimes.com/2021/09/30/health/youth-vaping-decline.html
113. U.S. Food and Drug Administration. FDA launches campaign aimed at preventing e-cigarette use among American Indian/Alaska Native Youth. Accessed: July 6, 2022. Available from: https://www.fda.gov/news-events/press-announcements/fda-launches-campaign-aimed-preventing-e-cigarette-use-among-american-indianalaska-native-youth
114. Piercy KL, et al. The physical activity guidelines for Americans. JAMA 2018;320:2020-8.
115. Matthews CE, et al. Amount and intensity of leisure-time physical activity and lower cancer risk. J Clin Oncol 2020;38:686-97.
116. Patel AV, et al. American College of Sports Medicine Roundtable Report on physical activity, sedentary behavior, and cancer prevention and control. Med Sci Sports Exerc 2019;51:2391-402.
117. Moore SC, et al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Intern Med 2016;176:816-25.
118. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project. Expert Report 2018. Lactation and the risk of cancer. Accessed: Available from: https://www.wcrf.org/diet-activity-and-cancer/
119. Clinton SK, et al. The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on diet, nutrition, physical activity, and cancer: Impact and future directions. J Nutr 2020;150:663-71.
120. Lauby-Secretan B, et al. Body fatness and cancer–Viewpoint of the IARC Working Group. N Engl J Med 2016;375:794-8.
121. Sengupta R, et al. AACR Cancer Progress Report 2019: Transforming lives through innovative cancer science. Clin Cancer Res 2019;25:5431.
122. Centers for Disease Control and Prevention. Adult obesity prevalence maps. Accessed: July 6, 2022. Available from: https://www.cdc.gov/obesity/data/prevalence-maps.html
123. State of Childhood Obesity. 2021 report: From crisis to opportunity. Accessed: July 6, 2022. Available from: https://stateofchildhoodobesity.org/2021report/
124. Restrepo BJ. Obesity prevalence among U.S. adults during the COVID-19 pandemic. Am J Prev Med 2022;63:102-6.
125. Lange SJ, et al. Longitudinal trends in body mass index before and during the COVID-19 pandemic among persons aged 2-19 years – United States, 2018-2020. MMWR Morb Mortal Wkly Rep 2021;70:1278-83.
126. Cawley J, et al. Direct medical costs of obesity in the United States and the most populous states. J Manag Care Spec Pharm 2021;27:354-66.
127. Trust for America’s Health. The state of obesity 2021. Accessed: July 6, 2022. Available from: https://tfah.org/stateofobesity2021
128. Geserick M, et al. Acceleration of BMI in early childhood and risk of sustained obesity. N Engl J Med 2018;379:1303-12.
129. Ward ZJ, et al. Simulation of growth trajectories of childhood obesity into adulthood. N Engl J Med 2017;377:2145-53.
130. Zohar L, et al. Adolescent overweight and obesity and the risk for pancreatic cancer among men and women: a nationwide study of 1.79 million Israeli adolescents. Cancer 2019;125:118-26.
131. Ellison-Barnes A, et al. Trends in obesity prevalence among adults aged 18 through 25 years, 1976-2018. JAMA 2021;326:2073-4.
132. Tao W, et al. Cancer risk after bariatric surgery in a cohort study from the five nordic countries. Obes Surg 2020;30:3761-7.
133. Schauer DP, et al. Bariatric surgery and the risk of cancer in a large multisite cohort. Ann Surg 2019;269:95-101.
134. Aminian A, et al. Association of bariatric surgery with cancer risk and mortality in adults with obesity. JAMA 2022;327:2423-33.
135. Shams-White MM, et al. The 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) score and all-cause, cancer, and cardiovascular disease mortality risk: A longitudinal analysis in the nih-aarp diet and health study. Curr Dev Nutr 2022;6:nzac096.
136. Phillips JA. Dietary guidelines for Americans, 2020-2025. Workplace Health Saf 2021;69:395.
137. Zhang FF, et al. Preventable cancer burden associated with poor diet in the united states. JNCI Cancer Spectr 2019;3:pkz034.
138. Lee SH, et al. Adults meeting fruit and vegetable intake recommendations – United States, 2019. MMWR Morb Mortal Wkly Rep 2022;71:1-9.
139. Wang L, et al. Trends in consumption of ultraprocessed foods among US youths aged 2-19 years, 1999-2018. JAMA 2021;326:519-30.
140. McCullough ML, et al. Association of socioeconomic and geographic factors with diet quality in US adults. JAMA Netw Open 2022;5:e2216406.
141. Althoff T, et al. Large-scale diet tracking data reveal disparate associations between food environment and diet. Nat Commun 2022;13:267.
142. Fadnes LT, et al. Estimating impact of food choices on life expectancy: A modeling study. PLoS Med 2022;19:e1003889.
143. Daepp MIG, et al. WIC food package changes: Trends in childhood obesity prevalence. Pediatrics 2019;143.
144. Pan L, et al. State-specific prevalence of obesity among children aged 2-4 years enrolled in the special supplemental nutrition program for women, infants, and children – United States, 2010-2016. MMWR Morb Mortal Wkly Rep 2019;68:1057-61.
145. Berkowitz SA, et al. Association of a fruit and vegetable subsidy program with food purchases by individuals with low income in the US. JAMA Netw Open 2021;4:e2120377.
146. Minihan AK, et al. Proportion of cancer cases attributable to physical inactivity by US State, 2013-2016. Med Sci Sports Exerc 2022;54:417-23.
147. Momma H, et al. Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: a systematic review and meta-analysis of cohort studies. Br J Sports Med 2022;56:755-63.
148. Saint-Maurice PF, et al. Estimated number of deaths prevented through increased physical activity among US adults. JAMA Intern Med 2022;182:349-52.
149. Heitz E. Quickstats: Percentage of adults aged ≥18 years who met the federal guidelines for muscle-strengthening physical activity, by age group and sex – National Health Interview Survey, United States, 2020. MMWR Morb Mortal Wkly Rep 2022;71:642.
150. Paluch AE, et al. Steps per day and all-cause mortality in middle-aged adults in the coronary artery risk development in young adults study. JAMA Netw Open 2021;4:e2124516.

References 151-200

151. Islami F, et al. American Cancer Society’s report on the status of cancer disparities in the United States, 2021. CA Cancer J Clin 2022;72:112-43.
152. World Cancer Research Fund. Diet, activity and cancer. Accessed: July 6, 2022. Available from: https://www.wcrf.org/diet-activity-and-cancer/
153. Papadimitriou N, et al. An umbrella review of the evidence associating diet and cancer risk at 11 anatomical sites. Nat Commun 2021;12:4579.
154. LoConte NK, et al. Alcohol and cancer: A statement of the American Society of Clinical Oncology. J Clin Oncol 2018;36:83-93.
155. White AJ, et al. Lifetime alcohol intake, binge drinking behaviors, and breast cancer risk. Am J Epidemiol 2017;186:541-9.
156. Xi B, et al. Relationship of alcohol consumption to all-cause, cardiovascular, and cancer-related mortality in U.S. Adults. J Am Coll Cardiol 2017;70:913-22.
157. Bassett JK, et al. Alcohol intake trajectories during the life course and risk of alcohol-related cancer: A prospective cohort study. Int J Cancer 2022;151:56-66.
158. GBD Alcohol Collaborators. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. Lancet 2022;400:185-235.
159. Goding Sauer A, et al. Proportion of cancer cases and deaths attributable to alcohol consumption by US state, 2013-2016. Cancer Epidemiol 2021;71:101893.
160. Bandi P, et al. Updated review of major cancer risk factors and screening test use in the United States in 2018 and 2019, with a focus on smoking cessation. Cancer Epidemiol Biomarkers Prev 2021;30:1287-99.
161. Pollard MS, et al. Changes in adult alcohol use and consequences during the COVID-19 pandemic in the US. JAMA Netw Open 2020;3:e2022942.
162. Roberts A, et al. Alcohol and other substance use during the COVID-19 pandemic: A systematic review. Drug Alcohol Depend 2021;229:109150.
163. Bohm MK, et al. Binge drinking among adults, by select characteristics and state – United States, 2018. MMWR Morb Mortal Wkly Rep 2021;70:1441-6.
164. Seidenberg AB, et al. Awareness of alcohol as a carcinogen and support for alcohol control policies. Am J Prev Med 2022;62:174-82.
165. American Society of Clinical Oncology. ASCO 2019 cancer opinion survey. Accessed: July 28, 2022. Available from: https://www.asco.org/research-data/reports-studies/national-cancer-opinion-survey
166. Centers for Disease Control and Prevention. Incidence of malignant melanoma of the skin–United States, 2009–2018 Accessed: July 6, 2022. Available from: https://www.cdc.gov/cancer/uscs/about/data-briefs/no28-melanoma-2018.htm
167. Strome A, et al. Assessment of sun protection knowledge and behaviors of US youth. JAMA Netw Open 2021;4:e2134550.
168. Cheng CE, et al. Health disparities among different ethnic and racial middle and high school students in sun exposure beliefs and knowledge. J Adolesc Health 2010;47:106-9.
169. Summers P, et al. Sunscreen use: Non-Hispanic Blacks compared with other racial and/or ethnic groups. Arch Dermatol 2011;147:863-4.
170. Mansh M, et al. Indoor tanning and melanoma: are gay and bisexual men more at risk? Melanoma Manag 2016;3:89-92.
171. Mansh M, et al. Association of skin cancer and indoor tanning in sexual minority men and women. JAMA Dermatol 2015;151:1308-16.
172. Stapleton JL, et al. Prevalence and location of indoor tanning among high school students in new jersey 5 years after the enactment of youth access restrictions. JAMA Dermatol 2020;156:1223-7.
173. Eskander A, et al. To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma. Cancer 2021;127:2333-41.
174. Eden M, et al. Cost-effectiveness of a policy-based intervention to reduce melanoma and other skin cancers associated with indoor tanning. Br J Dermatol 2022;187:105-14.
175. American Cancer Society. Cancer Prevention & Early Detection Facts and Figures 2021-2022. Accessed: July 6, 2022. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-prevention-and-early-detection-facts-and-figures/2021-cancer-prevention-and-early-detection.pdf
176. National Cancer Institute. Cancer Trends Progress Report. Accessed: July 6, 2022. Available from: https://progressreport.cancer.gov/
177. de Martel C, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020;8:e180-e90.
178. Hong CY, et al. Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study. J Viral Hepat 2020;27:896-903.
179. Lemaitre M, et al. Hepatitis b virus associated b-cell non-Hodgkin lymphoma in non-endemic areas. Blood 2018;132:4228-.
180. Couronne L, et al. From hepatitis C virus infection to B-cell lymphoma. Ann Oncol 2018;29:92-100.
181. Centers for Disease Control and Prevention. Rates of reported acute Hepatitis B virus infection, by age group — United States, 2004–2019. Accessed: July 6, 2022. Available from: https://www.cdc.gov/hepatitis/statistics/2019surveillance/Figure2.4.htm
182. Weng MK, et al. Universal Hepatitis B vaccination in adults aged 19-59 years: Updated recommendations of the advisory committee on immunization practices – United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:477-83.
183. Ye Q, et al. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J Hepatol 2022;76:63-74.
184. Jones P, et al. A mixed-methods approach to understanding perceptions of hepatitis B and hepatocellular carcinoma among ethnically diverse Black communities in South Florida. Cancer Causes Control 2020;31:1079-91.
185. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report 2019. Accessed: July 6, 2022. Available from: https://www.cdc.gov/hepatitis/statistics/2019surveillance/HepC.htm
186. Alvarez EG, et al. Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture. Nat Commun 2021;12:6910.
187. U.S. Department of Health and Human Services. Viral Hepatitis national strategic plan for the United States: A Roadmap to elimination (2021–2025). Accessed: June 30, 2022. Available from: https://www.hhs.gov/hepatitis/index.html
188. Centers for Disease Control and Prevention. Basic information about HPV and cancer. Accessed: July 28, 2022. Available from: https://www.cdc.gov/cancer/hpv/basic_info/
189. Rosenblum HG, et al. Human papillomavirus vaccine impact and effectiveness through 12 years after vaccine introduction in the United States, 2003 to 2018. Ann Intern Med 2022;175:918-26.
190. Liao CI, et al. Trends in Human papillomavirus-associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017. JAMA Netw Open 2022;5:e222530.
191. Falcaro M, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 2021;398:2084-92.
192. Tabibi T, et al. Human papillomavirus vaccination and trends in cervical cancer incidence and mortality in the US. JAMA Pediatr 2022;176:313-6.
193. Berenson AB, et al. Association of human papillomavirus vaccination with the incidence of squamous cell carcinomas of the anus in the US. JAMA Oncol 2022;8:1-3.
194. Pingali C, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years – United States, 2020. MMWR Morb Mortal Wkly Rep 2021;70:1183-90.
195. National Cancer Institute. HPV and Cancer. Accessed: August 11, 2022. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer
196. Basu P, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol 2021;22:1518-29.
197. Barnabas RV, et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evid 2022;1:EVIDoa2100056.
198. Sonawane K, et al. Trends in human papillomavirus vaccine safety concerns and adverse event reporting in the United States. JAMA Netw Open 2021;4:e2124502.
199. Giovannucci E, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010;60:207-21.
200. Zhu B, et al. The relationship between diabetes mellitus and cancers and its underlying mechanisms. Front Endocrinol (Lausanne) 2022;13:800995.

References 201-250

201. Shahid RK, et al. Diabetes and cancer: Risk, challenges, management and outcomes. Cancers (Basel) 2021;13.
202. Centers for Disease Control and Prevention. A snapshot: Diabetes in the United States. Accessed: July 6, 2022. Available from: https://www.cdc.gov/diabetes/library/socialmedia/infographics/diabetes.html
203. Centers for Disease Control and Prevention. Age-adjusted prevalence of diagnosed, undiagnosed, and total diabetes among adults aged 18 years or older, United States, 2017–2020. Accessed: July 6, 2022. Available from: https://www.cdc.gov/diabetes/data/statistics-report/appendix.html#tabs-1-1
204. Rey-Renones C, et al. Type 2 diabetes mellitus and cancer: Epidemiology, physiopathology and prevention. Biomedicines 2021;9.
205. American Diabetes Association. Comprehensive medical evaluation and assessment of comorbidities: Standards of medical care in diabetes-2019. Diabetes Care 2019;42:S34-S45.
206. Nichols HB, et al. Breast cancer risk after recent childbirth: A pooled analysis of 15 prospective studies. Ann Intern Med 2019;170:22-30.
207. Ambrosone CB, et al. Relationships between breast feeding and breast cancer subtypes: Lessons learned from studies in humans and in mice. Cancer Res 2020;80:4871-7.
208. Jung AY, et al. Distinct reproductive risk profiles for intrinsic-like breast cancer subtypes: pooled analysis of population-based studies. J Natl Cancer Inst 2022.
209. Vohra SN, et al. Molecular and clinical characterization of postpartum-associated breast cancer in the carolina breast cancer study phase I-III, 1993-2013. Cancer Epidemiol Biomarkers Prev 2022;31:561-8.
210. Hartman EK, et al. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis. Breast Cancer Res Treat 2016;160:347-60.
211. Shao C, et al. Prognosis of pregnancy-associated breast cancer: a meta-analysis. BMC Cancer 2020;20:746.
212. Lefrere H, et al. Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation. Int J Gynecol Cancer 2021;31:412-22.
213. Shagisultanova E, et al. Overall survival is the lowest among young women with postpartum breast cancer. Eur J Cancer 2022;168:119-27.
214. Goddard ET, et al. Association between postpartum breast cancer diagnosis and metastasis and the clinical features underlying risk. JAMA Netw Open 2019;2:e186997.
215. Jindal S, et al. Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes. Nat Commun 2021;12:6341.
216. Amant F, et al. The definition of pregnancy-associated breast cancer is outdated and should no longer be used. Lancet Oncol 2021;22:753-4.
217. Amant F, et al. Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. Eur J Cancer 2022;170:54-63.
218. Schedin P, et al. Can breast cancer prevention strategies be tailored to biologic subtype and unique reproductive windows? J Natl Cancer Inst 2022.
219. Millikan RC, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008;109:123-39.
220. Lord SJ, et al. Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case-control study. Cancer Epidemiol Biomarkers Prev 2008;17:1723-30.
221. Fortner RT, et al. Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses’ Health Studies. Breast Cancer Res 2019;21:40.
222. Moorman PG, et al. Reproductive factors and ovarian cancer risk in African-American women. Ann Epidemiol 2016;26:654-62.
223. Babic A, et al. Association between breastfeeding and ovarian cancer risk. JAMA Oncol 2020;6:e200421.
224. Anstey EH, et al. Breastfeeding and breast cancer risk reduction: Implications for black mothers. Am J Prev Med 2017;53:S40-S6.
225. Palmer JR, et al. Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst 2014;106.
226. John EM, et al. Reproductive history, breast-feeding and risk of triple negative breast cancer: The Breast Cancer Etiology in Minorities (BEM) study. Int J Cancer 2018;142:2273-85.
227. Ma H, et al. Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. Breast Cancer Res 2017;19:6.
228. Hoyt-Austin A, et al. Awareness that breastfeeding reduces breast cancer risk: 2015-2017 National Survey of Family Growth. Obstet Gynecol 2020;136:1154-6.
229. Chiang KV, et al. Racial and ethnic disparities in breastfeeding initiation horizontal line United States, 2019. MMWR Morb Mortal Wkly Rep 2021;70:769-74.
230. Beauregard JL, et al. Racial disparities in breastfeeding initiation and duration among U.S. infants born in 2015. MMWR Morb Mortal Wkly Rep 2019;68:745-8.
231. Chlebowski RT, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA 2020;324:369-80.
232. Chlebowski RT, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 2008;168:370-7; quiz 45.
233. Chlebowski RT, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-87.
234. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019;394:1159-68.
235. Wang SM, et al. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort. Breast Cancer Res 2020;22:129.
236. Vinogradova Y, et al. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ 2020;371:m3873.
237. Chlebowski RT, et al. Menopausal hormone therapy and breast cancer. Cancer J 2022;28:169-75.
238. Jackson SS, et al. Understanding the role of sex hormones in cancer for the transgender community. Trends Cancer 2022;8:273-5.
239. de Blok CJM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 2019;365:l1652.
240. de Nie I, et al. Prostate cancer incidence under androgen deprivation: Nationwide cohort study in trans women receiving hormone treatment. J Clin Endocrinol Metab 2020;105:e3293-9.
241. National Cancer Institute. Cancer Trends Progress Report. Accessed: July 28, 2022. Available from: https://progressreport.cancer.gov
242. U.S. Department of Health and Human Services. National Toxicology Program: 15th Report on Carcinogens. Accessed: July 13, 2022. Available from: https://ntp.niehs.nih.gov/whatwestudy/assessments/cancer/roc/index.html
243. ProPublica. How we created the most detailed map ever of cancer-causing industrial air pollution. Accessed: July 6, 2022. Available from: https://www.propublica.org/article/how-we-created-the-most-detailed-map-ever-of-cancer-causing-industrial-air-pollution
244. Loomis D, et al. The carcinogenicity of outdoor air pollution. Lancet Oncol 2013;14:1262-3.
245. Korsiak J, et al. Long-term exposure to wildfires and cancer incidence in Canada: a population-based observational cohort study. Lancet Planet Health 2022;6:e400-e9.
246. Oregon Public Broadcasting. Analysis suggests Oregon’s wildfire smoke comes with a side of cancer-causing chemicals. Accessed: July 28, 2022. Available from: https://www.opb.org/article/2021/12/27/oregon-wildfire-smoke-voc-cancer-air-quality-chemicals/
247. Crosby D, et al. Early detection of cancer. Science 2022;375:eaay9040.
248. de Koning HJ, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med 2020;382:503-13.
249. Meza R, et al. Impact of Joint Lung Cancer Screening and Cessation Interventions Under the New Recommendations of the U.S. Preventive Services Task Force. J Thorac Oncol 2022;17:160-6.
250. Sharma KP, et al. Preventing Breast, Cervical, and Colorectal Cancer Deaths: Assessing the Impact of Increased Screening. Prev Chronic Dis 2020;17:E123.

References 251-300

251. U.S. Preventive Services Task Force. Grade definitions. Accessed: June 30, 2022. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/grade-definitions
252. Yala A, et al. Toward robust mammography-based models for breast cancer risk. Sci Transl Med 2021;13.
253. National Cancer Institute. Artificial Intelligence. Accessed: June 30, 2022. Available from: https://www.cancer.gov/research/areas/diagnosis/artificial-intelligence
254. da Silva LM, et al. Independent real-world application of a clinical-grade automated prostate cancer detection system. J Pathol 2021;254:147-58.
255. Kim HE, et al. Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multireader study. Lancet Digit Health 2020;2:e138-e48.
256. Salim M, et al. External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms. JAMA Oncol 2020;6:1581-8.
257. Glissen Brown JR, et al. Deep Learning Computer-aided Polyp Detection Reduces Adenoma Miss Rate: A United States Multi-center Randomized Tandem Colonoscopy Study (CADeT-CS Trial). Clin Gastroenterol Hepatol 2022;20:1499-507 e4.
258. Cheng CL, et al. Comparison of Right Colon Adenoma Miss Rates Between Water Exchange and Carbon Dioxide Insufflation: A Prospective Randomized Controlled Trial. J Clin Gastroenterol 2021;55:869-75.
259. Ahn SB, et al. The Miss Rate for Colorectal Adenoma Determined by Quality-Adjusted, Back-to-Back Colonoscopies. Gut Liver 2012;6:64-70.
260. Iqbal MJ, et al. Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future. Cancer Cell Int 2021;21:270.
261. National Cancer Insititute. Human Tumor Atlas Network. Accessed: June 30, 2022. Available from: https://humantumoratlas.org/
262. Palefsky JM, et al. Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. N Engl J Med 2022;386:2273-82.
263. Cameron JM, et al. Multi-cancer early detection with a spectroscopic liquid biopsy platform. Research Square Platform LLC; 2022.
264. Sabatino SA, et al. Cancer Screening Test Receipt – United States, 2018. MMWR Morb Mortal Wkly Rep 2021;70:29-35.
265. Moss JL, et al. Geographic Variation in Overscreening for Colorectal, Cervical, and Breast Cancer Among Older Adults. JAMA Netw Open 2020;3:e2011645.
266. Brawley OW. On Breast Cancer Screening in Older Women. Ann Intern Med 2022;175:127-8.
267. Kotwal AA, et al. Cancer Screening Among Older Adults: a Geriatrician’s Perspective on Breast, Cervical, Colon, Prostate, and Lung Cancer Screening. Curr Oncol Rep 2020;22:108.
268. Schoenborn NL, et al. Racial disparities vary by patient life expectancy in screening for breast, prostate, and colorectal cancers. J Gen Intern Med 2020;35:3389-91.
269. Schoenborn NL, et al. Preferred clinician communication about stopping cancer screening among older us adults: Results from a national survey. JAMA Oncol 2018;4:1126-8.
270. Kaiser Family Foundation. Racial disparities in cancer outcomes, screening, and treatment. Accessed: July 15, 2022. Available from: https://www.kff.org/racial-equity-and-health-policy/issue-brief/racial-disparities-in-cancer-outcomes-screening-and-treatment/
271. Liu D, et al. Interventions to reduce healthcare disparities in cancer screening among minority adults: A systematic review. J Racial Ethn Health Disparities 2021;8:107-26.
272. Teglia F, et al. Global association of COVID-19 pandemic measures with cancer screening: A systematic review and meta-analysis. JAMA Oncol 2022.
273. Chen RC, et al. Association of cancer screening deficit in the United States with the COVID-19 pandemic. JAMA Oncol 2021;7:878-84.
274. Joung RH, et al. A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic. Cancer 2022;128:2119-25.
275. Wyatt LC, et al. Disparities in colorectal cancer screening among South Asians in New York City: a cross-sectional study. J Cancer Educ 2021.
276. Rustagi AS, et al. Likelihood of lung cancer screening by poor health status and race and ethnicity in US adults, 2017 to 2020. JAMA Netw Open 2022;5:e225318.
277. Viramontes O, et al. Colorectal cancer screening among Hispanics in the United States: Disparities, modalities, predictors, and regional variation. Prev Med 2020;138:106146.
278. McDaniel CC, et al. Persistent racial disparities in cervical cancer screening with Pap test. Prev Med Rep 2021;24:101652.
279. Shete S, et al. Differences in breast and colorectal cancer screening adherence among women residing in urban and rural communities in the United States. JAMA Netw Open 2021;4:e2128000.
280. Stenzel AE, et al. The intersection of sexual orientation with race and ethnicity in cervical cancer screening. Cancer 2022;128:2753-9.
281. Benavidez GA, et al. Disparities in meeting USPSTF breast, cervical, and colorectal cancer screening guidelines among women in the United States. Prev Chronic Dis 2021;18:E37.
282. Oladeru OT, et al. Breast and cervical cancer screening disparities in transgender people. Am J Clin Oncol 2022;45:116-21.
283. Phreesia Life Science and Kilck Health. Closing the gap: Boosting preventive care among LGBTQ+ patients. Accessed: July 28, 2022. Available from: https://engage.phreesia.com/rs/867-GML-252/images/Phreesia_Life_Sciences_Klick_Health-LGBTQ%2B_Preventive_Heath_Report.pdf
284. Brown JJ, et al. Decreased colorectal cancer incidence and mortality in a diverse urban population with increased colonoscopy screening. BMC Public Health 2021;21:1280.
285. Sun J, et al. The impact of medicare health insurance coverage on lung cancer screening. Med Care 2022;60:29-36.
286. Shokar NK, et al. Outcomes of a multicomponent culturally tailored cervical cancer screening intervention among underserved hispanic women (de Casa en Casa). Health Promot Pract 2021;22:112-21.
287. Huf SW, et al. Text messaging and opt-out mailed outreach in colorectal cancer screening: A randomized clinical trial. J Gen Intern Med 2021;36:1958-64.
288. Kindratt TB, et al. Email patient-provider communication and cancer screenings among US adults: Cross-sectional study. JMIR Cancer 2021;7:e23790.
289. National Academy of Sciences, Engineering, and Medicine. Guiding cancer control: A path to transformation. Accessed: July 28, 2022.
290. Centers for Disease Control and Prevention. Colorectal Cancer Control Program (CRCCP). Accessed: June 30, 2022. Available from: https://www.cdc.gov/cancer/crccp/
291. Maxwell AE, et al. Evaluating uptake of evidence-based interventions in 355 clinics partnering with the colorectal cancer control program, 2015-2018. Prev Chronic Dis 2022;19:E26.
292. Li A, et al. Clinical trial design: Past, present, and future in the context of big data and precision medicine. Cancer 2020;126:4838-46.
293. Hariton E, et al. Randomised controlled trials – the gold standard for effectiveness research: Study design: randomised controlled trials. BJOG 2018;125:1716.
294. Bakouny Z, et al. Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study. Ann Oncol 2022.
295. Aldrighetti CM, et al. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. JAMA Netw Open 2021;4:e2133205.
296. Falzone L, et al. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol 2018;9:1300.
297. Lawrence W. History of surgical oncology. In: Norton JA, Barie PS, Bollinger RR, Chang AE, Lowry SF, Mulvihill SJ, et al., editors. Surgery. New York, NY: Springer New York; 2008. p 1889-900.
298. Gianfaldoni S, et al. An overview on radiotherapy: From its history to its current applications in dermatology. Open Access Maced J Med Sci 2017;5:521-5.
299. DeVita VT, Jr., et al. A history of cancer chemotherapy. Cancer Res 2008;68:8643-53.
300. Dobashi Y, et al. Molecularly targeted therapy: past, present and future. Chemotherapy 2012;1:2.

References 301-350

301. Zhang Y, et al. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 2020;17:807-21.
302. Gachupin FC, et al. Renal cell carcinoma surgical treatment disparities in American Indian/Alaska Natives and Hispanic Americans in Arizona. Int J Environ Res Public Health 2022;19.
303. Taparra K, et al. Disaggregation of Asian American and Pacific Islander women with stage 0-II breast cancer unmasks disparities in survival and surgery-to-radiation intervals: A National Cancer Database analysis from 2004 to 2017. JCO Oncol Pract 2022:OP2200001.
304. Babatunde OA, et al. Racial disparities and diagnosis-to-treatment time among patients diagnosed with breast cancer in South Carolina. J Racial Ethn Health Disparities 2022;9:124-34.
305. Marrett E, et al. Factors associated with time to EGFR TKI treatment in patients with non-squamous metastatic non-small-cell lung cancer. Future Oncol 2022;18:1535-44.
306. Ahn JC, et al. Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology 2022.
307. Perera SK, et al. Global demand for cancer surgery and an estimate of the optimal surgical and anaesthesia workforce between 2018 and 2040: a population-based modelling study. Lancet Oncol 2021;22:182-9.
308. Burotto M, et al. Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes. Semin Oncol 2019;46:83-99.
309. Harter P, et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med 2021;385:2123-31.
310. Vergote IB, et al. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev 2015;34:41-52.
311. Tanyi JL, et al. Phase 3, randomized, single-dose, open-label study to investigate the safety and efficacy of pafolacianine sodium injection (OTL38) for intraoperative imaging of folate receptor positive ovarian cancer. Journal of Clinical Oncology 2021;39:5503-.
312. Maroongroge S, et al. Geographic access to radiation therapy facilities in the United States. Int J Radiat Oncol Biol Phys 2022;112:600-10.
313. Wang K, et al. Radiation therapy-associated toxicity: Etiology, management, and prevention. CA Cancer J Clin 2021;71:437-54.
314. Santoro M, et al. Recent applications of artificial intelligence in radiotherapy: Where we are and beyond. Applied Sciences-Basel 2022;12:3223.
315. Duan H, et al. Radiotheranostics – Precision medicine in nuclear medicine and molecular imaging. Nanotheranostics 2022;6:103-17.
316. American Association for Cancer Research. AACR Cancer Progress Report 2018. Accessed: June 30, 2022. Available from: https://cancerprogressreport.aacr.org/wp-content/uploads/sites/2/2020/09/AACR_CPR_2018.pdf
317. Sartor O, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385:1091-103.
318. Farolfi A, et al. Theragnostics in prostate cancer. Q J Nucl Med Mol Imaging 2021;65:333-41.
319. National cancer Institute. About rare cancers. Accessed: June 30, 2022. Available from: https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/about-rare-cancers
320. Kim LC, et al. Hypoxia-inducible factors in cancer. Cancer Res 2022;82:195-6.
321. Jonasch E, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med 2021;385:2036-46.
322. National Organization for Rare Disorders. Perivascular epithelioid cell neoplasm. Accessed: June 30, 2022. Available from: https://rarediseases.org/rare-diseases/perivascular-epithelioid-cell-neoplasm/
323. Zou Z, et al. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci 2020;10:31.
324. Wagner AJ, et al. nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors. J Clin Oncol 2021;39:3660-70.
325. Tommasini-Ghelfi S, et al. Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease. Sci Adv 2019;5:eaaw4543.
326. Dang L, et al. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol 2016;27:599-608.
327. Du X, et al. The Roles of 2-Hydroxyglutarate. Front Cell Dev Biol 2021;9:651317.
328. Jusakul A, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov 2017;7:1116-35.
329. Zhu AX, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: The phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 2021;7:1669-77.
330. Abou-Alfa GK, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020;21:796-807.
331. Lovly CM, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov 2014;4:889-95.
332. Antonescu CR, et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol 2015;39:957-67.
333. U.S. Food and Drug Administration. FDA approves crizotinib for ALK-positive inflammatory myofibroblastic tumor. Accessed: July 28, 2022. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-alk-positive-inflammatory-myofibroblastic-tumor
334. Cilloni D, et al. Molecular pathways: BCR-ABL. Clin Cancer Res 2012;18:930-7.
335. K KB, et al. Protein tyrosine kinases: Their roles and their targeting in leukemia. Cancers (Basel) 2021;13.
336. Rea D, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 2021;138:2031-41.
337. Hughes TP, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 2019;381:2315-26.
338. Weber ANR, et al. Bruton’s tyrosine kinase: An emerging key player in innate immunity. Front Immunol 2017;8:1454.
339. Lemmon MA, et al. Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117-34.
340. Hendriks RW, et al. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer 2014;14:219-32.
341. Yun S, et al. Waldenstrom macroglobulinemia: Review of pathogenesis and management. Clin Lymphoma Myeloma Leuk 2017;17:252-62.
342. Tam CS, et al. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia. Future Oncol 2018;14:2229-37.
343. Opat S, et al. The MAGNOLIA Trial: Zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma. Clin Cancer Res 2021;27:6323-32.
344. Phillips T, et al. Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv 2022;6:3472-9.
345. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115-23.
346. Minard-Colin V, et al. Rituximab for high-risk, mature B-cell non-Hodgkin’s lymphoma in children. N Engl J Med 2020;382:2207-19.
347. Dankner M, et al. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene 2018;37:3183-99.
348. U.S. Food and Drug Administration. FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. Accessed: June 30, 2022. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid
349. Tarantino P, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin 2022;72:165-82.
350. Unruh D, et al. Beyond thrombosis: the impact of tissue factor signaling in cancer. J Hematol Oncol 2020;13:93.

References 351-400

351. Pang SS, et al. Current management of locally advanced and metastatic cervical cancer in the United States. JCO Oncol Pract 2022;18:417-22.
352. Coleman RL, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22:609-19.
353. Chen J, et al. Expression and function of the epidermal growth factor receptor in physiology and disease. Physiol Rev 2016;96:1025-69.
354. da Cunha Santos G, et al. EGFR mutations and lung cancer. Annu Rev Pathol 2011;6:49-69.
355. Remon J, et al. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. Cancer Treat Rev 2020;90:102105.
356. Zhou C, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: A phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol 2021;7:e214761.
357. Harbeck N, et al. Breast cancer. Nat Rev Dis Primers 2019;5:66.
358. National Cancer Institute. Female breast cancer subtypes. Accessed: June 30, 2022. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html
359. Rimawi MF, et al. Targeting HER2 for the treatment of breast cancer. Annu Rev Med 2015;66:111-28.
360. Goel S, et al. CDK4/6 inhibition in cancer: Beyond cell cycle arrest. Trends Cell Biol 2018;28:911-25.
361. Pandey N, et al. Rapid detection and signaling of DNA damage by PARP-1. Trends Biochem Sci 2021;46:744-57.
362. Dobosz P, et al. The intriguing history of cancer immunotherapy. Front Immunol 2019;10:2965.
363. Waldman AD, et al. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020;20:651-68.
364. Han J, et al. Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy. Nat Cancer 2021;2:300-11.
365. Galluzzi L, et al. The hallmarks of successful anticancer immunotherapy. Sci Transl Med 2018;10.
366. Cancer Research Institute. Approval timelines of active immunotherapies. Accessed: June 30, 2022. Available from: https://www.cancerresearch.org/en-us/scientists/immuno-oncology-landscape/fda-approval-timeline-of-active-immunotherapies
367. Kubli SP, et al. Beyond immune checkpoint blockade: emerging immunological strategies. Nat Rev Drug Discov 2021;20:899-919.
368. Zhang L, et al. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomark Res 2022;10:12.
369. Daher M, et al. Outlook for new CAR-based therapies with a focus on CAR NK cells: What lies beyond CAR-engineered T cells in the race against cancer. Cancer Discov 2021;11:45-58.
370. Xie G, et al. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine 2020;59:102975.
371. Wang S, et al. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Med 2021;19:140.
372. Marin-Acevedo JA, et al. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol 2021;14:45.
373. Tawbi HA, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022;386:24-34.
374. Frampton AE, et al. A new combination immunotherapy in advanced melanoma. N Engl J Med 2022;386:91-2.
375. Forde PM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386:1973-85.
376. U.S. Food and Drug Administration. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors. Accessed: June 30, 2022. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors
377. Cercek A, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386:2363-76.
378. Uldrick TS, et al. Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. Sci Transl Med 2022;14:eabl3836.
379. Sedykh SE, et al. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther 2018;12:195-208.
380. Carvajal RD, et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol 2017;101:38-44.
381. Martinez-Perez D, et al. gp-100 as a novel therapeutic target in uveal melanoma. Cancers (Basel) 2021;13.
382. Damato BE, et al. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers (Basel) 2019;11.
383. Nathan P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med 2021;385:1196-206.
384. Rohaan MW, et al. Adoptive cellular therapies: the current landscape. Virchows Arch 2019;474:449-61.
385. Dana H, et al. CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B 2021;11:1129-47.
386. Morotti M, et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer 2021;124:1759-76.
387. Netsrithong R, et al. Advances in adoptive cell therapy using induced pluripotent stem cell-derived T cells. Front Immunol 2021;12:759558.
388. van de Donk NWCJ, et al. Multiple myeloma. The Lancet 2021;397:410-27.
389. Yu B, et al. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 2020;13:125.
390. Berdeja JG, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021;398:314-24.
391. Pulte D, et al. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS One 2014;9:e85554.
392. Shah BD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. The Lancet 2021;398:491-502.
393. Bojarczuk K, et al. Molecular classification of large b-cell non-hodgkin lymphoma. Cancer J 2020;26:357-61.
394. Fowler NH, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 2022;28:325-32.
395. Oh H, et al. The risk of psychological stress on cancer recurrence: A systematic review. Cancers (Basel) 2021;13:5816.
396. Hurria A, et al. Cancer Treatment as an Accelerated Aging Process: Assessment, Biomarkers, and Interventions. Am Soc Clin Oncol Educ Book 2016;35:e516-22.
397. Scott LC, et al. Predicted Heart Age Among Cancer Survivors – United States, 2013-2017. MMWR Morb Mortal Wkly Rep 2021;70:1-6.
398. Johnson DB, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 2022;19:254-67.
399. Rincones O, et al. An updated systematic review of quantitative studies assessing anxiety, depression, fear of cancer recurrence or psychological distress in testicular cancer survivors. Cancer Manag Res 2021;13:3803-16.
400. Perego M, et al. Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils. Sci Transl Med 2020;12:eabb5817.

References 401-450

401. Manigault AW, et al. Vulnerability to inflammation-related depressive symptoms: Moderation by stress in women with breast cancer. Brain Behav Immun 2021;94:71-8.
402. Breidenbach C, et al. Prevalence and determinants of anxiety and depression in long-term breast cancer survivors. BMC Psychiatry 2022;22:101.
403. Huynh NTT, et al. Nurse-led educational interventions for anxiety management in cancer survivors: a systematic review and meta-analysis. Support Care Cancer 2022;30:6699-744.
404. Heinrich M, et al. Suicide risk and mortality among patients with cancer. Nat Med 2022;28:852-9.
405. Chang WH, et al. Cumulative burden of psychiatric disorders and self-harm across 26 adult cancers. Nat Med 2022;28:860-70.
406. Bulotiene G, et al. Interventions for reducing suicide risk in cancer patients: A literature review. Eur J Psychol 2019;15:637-49.
407. Mollica MA, et al. Survivorship for individuals living with advanced and metastatic cancers: National Cancer Institute Meeting Report. J Natl Cancer Inst 2022;114:489-95.
408. Mollica MA, et al. Current state of funded National Institutes of Health grants focused on individuals living with advanced and metastatic cancers: a portfolio analysis. J Cancer Surviv 2021;15:370-4.
409. Yabroff KR, et al. Association of medical financial hardship and mortality among cancer survivors in the United States. J Natl Cancer Inst 2022;114:863-70.
410. Shankaran V, et al. S1417CD: A prospective multicenter cooperative group-led study of financial hardship in metastatic colorectal cancer patients. J Natl Cancer Inst 2022;114:372-80.
411. Fu SJ, et al. Out-of-pocket costs among patients with a new cancer diagnosis enrolled in high-deductible health plans vs traditional insurance. JAMA Netw Open 2021;4:e2134282.
412. Federal Reserve Board. Survey of household economics and decisionmaking. Accessed: June 30, 2022. Available from: https://www.federalreserve.gov/consumerscommunities/shed.htm
413. Shankaran V, et al. Risk of adverse financial events in patients with cancer: Evidence from a novel linkage between cancer registry and credit records. J Clin Oncol 2022;40:884-91.
414. Hussaini SMQ, et al. Financial toxicity of cancer treatment. JAMA Oncol 2022;8:788.
415. Friedes C, et al. Longitudinal trends of financial toxicity in patients with lung cancer: A prospective cohort study. JCO Oncol Pract 2021;17:e1094-e109.
416. Winkfield KM, et al. Addressing financial barriers to patient participation in clinical trials: ASCO policy statement. J Clin Oncol 2018:JCO1801132.
417. Unger JM, et al. The role of clinical trial participation in cancer research: Barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book 2016;35:185-98.
418. Unger JM, et al. Patient income level and cancer clinical trial participation: A prospective survey study. JAMA Oncol 2016;2:137-9.
419. Bex A, et al. A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914). Journal of Clinical Oncology 2020;38:TPS5099-TPS.
420. Prasad V, et al. Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: a cross sectional analysis. medRxiv 2022:2022.06.22.22276763.
421. National Cancer Institute. Cancer in children and adolescents. Accessed: April 22, 2022. Available from: https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet
422. Gibson TM, et al. Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 2018;19:1590-601.
423. Hudson MM, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013;309:2371-81.
424. Bhakta N, et al. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin’s lymphoma: an analysis from the St Jude Lifetime Cohort Study. Lancet Oncol 2016;17:1325-34.
425. Xie J, et al. Reproductive concerns among adolescent and young adult cancer survivors: A scoping review of current research situations. Cancer Med 2022.
426. Alliance for Fertility Preservation. State laws & legislation. Accessed: July 14, 2022. Available from: https://www.allianceforfertilitypreservation.org/state-legislation/
427. Stensheim H, et al. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 2009;27:45-51.
428. Morice P, et al. Gynaecological cancers in pregnancy. Lancet 2012;379:558-69.
429. Giuntoli RL, 2nd, et al. Evaluation and management of adnexal masses during pregnancy. Clin Obstet Gynecol 2006;49:492-505.
430. Litton JK, et al. Breast cancer and pregnancy: current concepts in diagnosis and treatment. Oncologist 2010;15:1238-47.
431. Jhaveri MB, et al. Melanoma in pregnancy. Clin Obstet Gynecol 2011;54:537-45.
432. Esposito S, et al. Chemotherapy against cancer during pregnancy: A systematic review on neonatal outcomes. Medicine (Baltimore) 2016;95:e4899.
433. Van Calsteren K, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol 2010;28:683-9.
434. Amant F, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med 2015;373:1824-34.
435. van Gerwen M, et al. Association of chemotherapy timing in pregnancy with congenital malformation. JAMA Netw Open 2021;4:e2113180.
436. Ebert U, et al. Cytotoxic therapy and pregnancy. Pharmacol Ther 1997;74:207-20.
437. Cardonick E, et al. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Ann Oncol 2012;23:3016-23.
438. Cardonick E, et al. Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy. Obstet Gynecol 2012;120:1267-72.
439. Gziri MM, et al. Effects of chemotherapy during pregnancy on the maternal and fetal heart. Prenat Diagn 2012;32:614-9.
440. Duncan PG, et al. Fetal risk of anesthesia and surgery during pregnancy. Anesthesiology 1986;64:790-4.
441. Ni Mhuireachtaigh R, et al. Anesthesia in pregnant patients for nonobstetric surgery. J Clin Anesth 2006;18:60-6.
442. Malhotra A, et al. Propofol’s effects on the fetal brain for non-obstetric surgery. Brain Sci 2017;7.
443. Streffer C, et al. Biological effects after prenatal irradiation (embryo and fetus). A report of the International Commission on Radiological Protection. Ann ICRP 2003;33:5-206.
444. Borgers JSW, et al. Immunotherapy for cancer treatment during pregnancy. Lancet Oncol 2021;22:e550-e61.
445. Lambertini M, et al. Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev 2015;41:301-9.
446. Dixon SB, et al. Racial and ethnic disparities in neurocognitive, emotional, and quality-of-life outcomes in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 2019;125:3666-77.
447. Abdelhadi OA, et al. Psychological distress and associated additional medical expenditures in adolescent and young adult cancer survivors. Cancer 2022;128:1523-31.
448. Ghazal LV, et al. Financial toxicity in adolescents and young adults with cancer: A concept analysis. Cancer Nurs 2021;44:E636-E51.
449. Meernik C, et al. Material and psychological financial hardship related to employment disruption among female adolescent and young adult cancer survivors. Cancer 2020;127:137-48.
450. Murphy CC, et al. Disparities in cancer survival among adolescents and young adults: A population-based study of 88 000 patients. J Natl Cancer Inst 2021;113:1074-83.

References 451-500

451. Linendoll N, et al. Adolescent and young adult survivorship care: Emerging from the COVID-19 pandemic stronger through teleoncology. J Adolesc Young Adult Oncol 2022;0:null.
452. Coltin H, et al. Locus-of-care disparities in end-of-life care intensity among adolescents and young adults with cancer: A population-based study using the IMPACT cohort. Cancer 2022;128:326-34.
453. Mohile SG, et al. Improving the quality of survivorship for older adults with cancer. Cancer 2016;122:2459-568.
454. Outlaw D, et al. Is the lack of evidence in older adults with cancer compromising safety? Expert Opin Drug Saf 2020;19:1059-61.
455. Siddique A, et al. Functional decline among older cancer survivors in the Baltimore longitudinal study of aging. J Am Geriatr Soc 2021;69:3124-33.
456. Fitch MI, et al. Main challenges in survivorship transitions: Perspectives of older adults with cancer. J Geriatr Oncol 2021;12:632-40.
457. Centers for Disease Control and Prevention. Prescription drug use among adults aged 40–79 in the United States and Canada. Accessed: July 28, 2022. Available from: https://www.cdc.gov/nchs/products/databriefs/db347.htm
458. Fitch MI, et al. Measuring quality of life in older people with cancer. Curr Opin Support Palliat Care 2021;15:39-47.
459. Fitch MI, et al. Challenges of survivorship for older adults diagnosed with cancer. Curr Oncol Rep 2022;24:763-73.
460. Nishijima TF, et al. A 10-item frailty index based on a comprehensive geriatric assessment (FI-CGA-10) in older adults with cancer: Development and construct validation. Oncologist 2021;26:e1751-e60.
461. Overcash J, et al. Comprehensive geriatric assessment as a versatile tool to enhance the care of the older person diagnosed with cancer. Geriatrics 2019;4:39.
462. Kwan ML, et al. Race/ethnicity, genetic ancestry, and breast cancer-related lymphedema in the Pathways Study. Breast Cancer Res Treat 2016;159:119-29.
463. Jagsi R, et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol 2014;32:1269-76.
464. Printz C. An expanded role for exercise in cancer treatment and survivorship: Backed by a trove of studies regarding the benefits of physical activity for patients with cancer and cancer survivors, researchers have updated exercise guidelines for these groups. Cancer 2020;126:2731-2.
465. Langlais CS, et al. Post-diagnostic dietary and lifestyle factors and prostate cancer recurrence, progression, and mortality. Curr Oncol Rep 2021;23:37.
466. Cao C, et al. Association of daily sitting time and leisure-time physical activity with survival among US cancer survivors. JAMA Oncol 2022;8:395-403.
467. Morishita S, et al. Effect of Exercise on Mortality and Recurrence in Patients With Cancer: A Systematic Review and Meta-Analysis. Integr Cancer Ther 2020;19:1534735420917462.
468. Cannioto RA, et al. Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. J Natl Cancer Inst 2021;113:54-63.
469. Bruce J, et al. Exercise versus usual care after non-reconstructive breast cancer surgery (UK PROSPER): multicentre randomised controlled trial and economic evaluation. BMJ 2021;375:e066542.
470. Rose GL, et al. The effects of exercise on the bone health of people with cancer: a systematic review and meta-analysis. Osteoporosis International 2022;33:327-38.
471. American College of Sports Medicine. Does physical activity mitigate the risk of frailty-related bone fractures among cancer survivors? Accessed: June 30, 2022. Available from: https://www.abstractsonline.com/pp8/#!/10504/presentation/2268
472. Naaktgeboren WR, et al. Physical activity and cardiac function in long-term breast cancer survivors: A cross-sectional study. JACC CardioOncol 2022;4:183-91.
473. Coughlin SS, et al. Cardiovascular disease among breast cancer survivors. Cardiovasc Disord Med 2020;2.
474. Forner JK, et al. Quality of life: A nurse-led physical activity coaching program to improve the quality of life of patients with cancer during the COVID-19 pandemic. Clin J Oncol Nurs 2021;25:571-7.
475. Kurz E, et al. Exercise-induced engagement of the IL-15/IL-15Ralpha axis promotes anti-tumor immunity in pancreatic cancer. Cancer Cell 2022;40:720-37 e5.
476. Drugs.Com. Exercise amplifies immune attack on pancreatic cancer. Accessed: July 6, 2022. Available from: https://www.drugs.com/clinical_trials/exercise-amplifies-immune-attack-pancreatic-cancer-20189.html
477. ClinicalTrials.Gov. Preoperative rehabilitation during neoadjuvant therapy for pancreatic cancer. Accessed: July 14, 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT02295956
478. Rock CL, et al. American Cancer Society nutrition and physical activity guideline for cancer survivors. CA: A Cancer Journal for Clinicians 2022;72:230-62.
479. The ASCO Post Staff. Study links diabetes and worse outcomes in long-term survivors of metastatic breast cancer. Accessed: July 14, 2022. Available from: https://ascopost.com/news/june-2022/study-links-diabetes-and-worse-outcomes-in-long-term-survivors-of-metastatic-breast-cancer/
480. Gany F, et al. Food to overcome outcomes disparities: A randomized controlled trial of food insecurity interventions to improve cancer outcomes. J Clin Oncol 2022:JCO2102400.
481. Fox JL, et al. The effect of smoking status on survival following radiation therapy for non-small cell lung cancer. Lung Cancer 2004;44:287-93.
482. Gritz ER, et al. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Cancer Epidemiol Biomarkers Prev 2005;14:2287-93.
483. Jensen K, et al. Smoking has a negative impact upon health related quality of life after treatment for head and neck cancer. Oral Oncol 2007;43:187-92.
484. Videtic GM, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003;21:1544-9.
485. Sheikh M, et al. Postdiagnosis smoking cessation and reduced risk for lung cancer progression and mortality : A prospective cohort study. Ann Intern Med 2021;174:1232-9.
486. Levy DE, et al. Cost-effectiveness of implementing smoking cessation interventions for patients with cancer. JAMA Netw Open 2022;5:e2216362.
487. Radbruch L, et al. Redefining palliative care-A new consensus-based definition. J Pain Symptom Manage 2020;60:754-64.
488. Chung V, et al. Improving palliative care and quality of life in pancreatic cancer patients. J Palliat Med 2022;25:720-7.
489. Sedhom R, et al. How palliative care teams can mitigate financial toxicity in cancer care. Support Care Cancer 2021;29:6175-7.
490. Ferrell B, et al. A palliative care intervention for patients on phase 1 studies. J Palliat Med 2021;24:846-56.
491. Nelson AM, et al. Palliative care and coping in patients with acute myeloid leukemia: Mediation analysis of data from a randomized clinical trial. Cancer 2021;127:4702-10.
492. Henrikson NB, et al. Patient and oncologist discussions about cancer care costs. Support Care Cancer 2014;22:961-7.
493. Kelly RJ, et al. Patients and physicians can discuss costs of cancer treatment in the clinic. J Oncol Pract 2015;11:308-12.
494. Yabroff KR, et al. Improving the process of screening for medical financial hardship in oncology practice. Cancer Epidemiol Biomarkers Prev 2021;30:593-6.
495. Pisu M, et al. How, when, and with whom should cost of care conversations occur? Preferences of two distinct cancer survivor groups. JCO Oncol Pract 2020;16:e912-e21.
496. Lang-Rollin I, et al. Psycho-oncology. Dialogues Clin Neurosci 2018;20:13-22.
497. Gregoire C, et al. Psycho-oncology interventions focusing on fatigue and sleep disturbances. Curr Opin Oncol 2022;34:270-8.
498. Dos Santos M, et al. Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: A 3-arm randomized trial. Cancer 2020;126:5328-36.
499. Lleras de Frutos M, et al. Video conference vs face-to-face group psychotherapy for distressed cancer survivors: A randomized controlled trial. Psychooncology 2020;29:1995-2003.
500. Fu X, et al. Research progress on influencing factors and intervention measures of post-traumatic growth in breast cancer patients. Front Public Health 2022;10:927370.

References 501-550

501. Menger F, et al. Post-traumatic growth after cancer: a scoping review of qualitative research. Support Care Cancer 2021;29:7013-27.
502. Moye J, et al. Making meaning of cancer: A qualitative analysis of oral-digestive cancer survivors’ reflections. J Health Psychol 2020;25:1222-35.
503. Steinberg DM, et al. “It made me the person I am today…”: Survivors of childhood, adolescent, and young adult cancer reflect on their experiences. J Adolesc Young Adult Oncol 2020;9:239-46.
504. Sumalla EC, et al. Posttraumatic growth in cancer: reality or illusion? Clin Psychol Rev 2009;29:24-33.
505. Fong AJ, et al. Survivorship transition care experiences and preparedness for survivorship among a diverse population of cancer survivors in New Jersey. Eur J Cancer Care (Engl) 2022;31:e13553.
506. Gorin SS, et al. Cancer care coordination: A systematic review and meta-analysis of over 30 years of empirical studies. Ann Behav Med 2017;51:532-46.
507. Trindade LF, et al. Effectiveness of care transition strategies for colorectal cancer patients: a systematic review and meta-analysis. Support Care Cancer 2022;30:6251-61.
508. Del Vecchio NJ, et al. Relationships between health literacy, having a cancer care coordinator, and long-term health-related quality of life among cancer survivors. Support Care Cancer 2021;29:7913-24.
509. National Partnership for Women and Families. Paid leave could keep more than 6 million caregivers connected to the labor force by 2030. Accessed: June 30, 2022. Available from: https://www.nationalpartnership.org/our-work/resources/economic-justice/paid-leave/paid-leave-caregivers-connected-2030.pdf
510. Longacre ML, et al. Cancer caregiving while employed: Caregiving roles, employment adjustments, employer assistance, and preferences for support. J Cancer Educ 2021;36:920-32.
511. Bradley CJ. Economic burden associated with cancer caregiving. Semin Oncol Nurs 2019;35:333-6.
512. Sadigh G, et al. Correlates of financial toxicity in adult cancer patients and their informal caregivers. Support Care Cancer 2022;30:217-25.
513. Washington Center for Equitable Growth. Paid medical leave research – equitable growth. Accessed: June 30, 2022. Available from: http://www.equitablegrowth.org/research-paper/paid-medical-leave-research/
514. AARP. What states offer paid family leave for caregivers? Accessed: June 30, 2022. Available from: https://www.aarp.org/caregiving/financial-legal/info-2019/paid-family-leave-laws.html
515. American Cancer Society. Survey: Cancer patients and survivors embrace telehealth. Accessed: June 30, 2022. Available from: https://www.fightcancer.org/releases/survey-cancer-patients-and-survivors-embrace-telehealth
516. Arem H, et al. Cancer provider and survivor experiences with telehealth during the COVID-19 pandemic. JCO Oncol Pract 2022;18:e452-e61.
517. Larson JL, et al. The effect of telehealth interventions on quality of life of cancer survivors: A systematic review and meta-analysis. Health Informatics J 2020;26:1060-78.
518. Del Monte U. Does the cell number 10(9) still really fit one gram of tumor tissue? Cell Cycle 2009;8:505-6.
519. Razeghian E, et al. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies. Stem Cell Res Ther 2021;12:428.
520. Mullard A. Targeted protein degraders crowd into the clinic. Nat Rev Drug Discov 2021;20:247-50.
521. Samarasinghe KTG, et al. Targeted protein degradation: A promise for undruggable proteins. Cell Chem Biol 2021;28:934-51.
522. Zong C, et al. Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science 2012;338:1622-6.
523. Navin N, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011;472:90-4.
524. Wu R, et al. Comprehensive analysis of spatial architecture in primary liver cancer. Sci Adv 2021;7:eabg3750.
525. Betge J, et al. The drug-induced phenotypic landscape of colorectal cancer organoids. Nat Commun 2022;13:3135.
526. Mao CP, et al. Protein detection in blood with single-molecule imaging. Sci Adv 2021;7.
527. Ursu O, et al. Massively parallel phenotyping of coding variants in cancer with Perturb-seq. Nat Biotechnol 2022;40:896-905.
528. Seryakov A, et al. RNA sequencing for personalized treatment of metastatic leiomyosarcoma: Case report. Front Oncol 2021;11:666001.
529. Newman S, et al. Genomes for kids: The scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing. Cancer Discov 2021;11:3008-27.
530. Ho DW, et al. Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. Nat Commun 2021;12:3684.
531. Mund A, et al. Deep visual proteomics defines single-cell identity and heterogeneity. Nat Biotechnol 2022.
532. Paulson TG, et al. Somatic whole genome dynamics of precancer in Barrett’s esophagus reveals features associated with disease progression. Nat Commun 2022;13:2300.
533. Sutera P, et al. Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate 2022;82 Suppl 1:S73-S85.
534. Yamoah K, et al. Novel transcriptomic interactions between immune content and genomic classifier predict lethal outcomes in high-grade prostate cancer. Eur Urol 2022;81:325-30.
535. Rayford W, et al. Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Commun Biol 2021;4:670.
536. Esteva A, et al. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med 2022;5:71.
537. Gardner L, et al. Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome. Nat Rev Clin Oncol 2022;19:551-61.
538. Harel M, et al. Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade. J Immunother Cancer 2022;10.
539. Steele CD, et al. Signatures of copy number alterations in human cancer. Nature 2022;606:984-91.
540. Dohmen J, et al. Identifying tumor cells at the single-cell level using machine learning. Genome Biol 2022;23:123.
541. Mahmood H, et al. Artificial Intelligence-based methods in head and neck cancer diagnosis: an overview. Br J Cancer 2021;124:1934-40.
542. Nassif AB, et al. Breast cancer detection using artificial intelligence techniques: A systematic literature review. Artif Intell Med 2022;127:102276.
543. Bera K, et al. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol 2022;19:132-46.
544. Wallace MB, et al. Impact of artificial intelligence on miss rate of colorectal neoplasia. Gastroenterology 2022;163:295-304 e5.
545. Liu WC, et al. Using machine learning methods to predict bone metastases in breast infiltrating ductal carcinoma patients. Front Public Health 2022;10:922510.
546. Guo LN, et al. Bias in, bias out: Underreporting and underrepresentation of diverse skin types in machine learning research for skin cancer detection-A scoping review. J Am Acad Dermatol 2022;87:157-9.
547. Obermeyer Z, et al. Dissecting racial bias in an algorithm used to manage the health of populations. Science 2019;366:447-53.
548. Uche-Anya E, et al. Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity. Gut 2022:gutjnl-2021-326271.
549. Yala A, et al. Multi-institutional validation of a mammography-based breast cancer risk model. J Clin Oncol 2022;40:1732-40.
550. Derbal Y. Can artificial intelligence improve cancer treatments? Health Informatics J 2022;28:14604582221102314.

References 551-600

551. McIntosh C, et al. Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer. Nat Med 2021;27:999-1005.
552. Corredor G, et al. An imaging biomarker of tumor-infiltrating lymphocytes to risk-stratify patients with HPV-associated oropharyngeal cancer. J Natl Cancer Inst 2022;114:609-17.
553. Naranbhai V, et al. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. The Lancet Oncology 2022;23:172-84.
554. Jaiswal A, et al. An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. Cancer Cell 2022;40:524-44 e5.
555. Mariathasan S, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 2018;554:544-8.
556. Wang L, et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun 2018;9:3503.
557. Wang S, et al. Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa. J Transl Med 2021;19:39.
558. Jensen C, et al. Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy. J Exp Clin Cancer Res 2021;40:326.
559. Jensen C, et al. Granzyme B degraded type IV Collagen products in serum identify melanoma patients responding to immune checkpoint blockade. Cancers (Basel) 2020;12.
560. Karsdal MA, et al. Novel combinations of post-translational modification (PTM) neo-epitopes provide tissue-specific biochemical markers–are they the cause or the consequence of the disease? Clin Biochem 2010;43:793-804.
561. Leeming DJ, et al. Post-translational modifications of the extracellular matrix are key events in cancer progression: opportunities for biochemical marker development. Biomarkers 2011;16:193-205.
562. Penn Today. Decade-long remission after CAR T cell therapy. Accessed: June 30, 2022. Available from: https://penntoday.upenn.edu/news/decade-long-remission-after-car-t-cell-therapy
563. Children’s Hospital of Philadelphia. First child to receive revolutionary CAR T therapy celebrates 10 years cancer free. Accessed: June 30, 2022. Available from: https://www.chop.edu/news/first-child-receive-revolutionary-car-t-therapy-celebrates-10-years-cancer-free
564. Stat News. ‘How do you decide?’: Cancer treatment’s CAR-T crisis has patients dying on a waitlist. Accessed: June 30, 2022. Available from: https://www.statnews.com/2022/06/02/car-t-crisis-cancer-patients-die-waiting/
565. Sterner RC, et al. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 2021;11:69.
566. Novartis. Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021. Accessed: June 30, 2022. Available from: https://www.novartis.com/news/media-releases/novartis-announces-t-chargetm-next-generation-car-t-platform-first-human-data-ash-2021
567. Ghassemi S, et al. Rapid manufacturing of non-activated potent CAR T cells. Nat Biomed Eng 2022;6:118-28.
568. Parayath NN, et al. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun 2020;11:6080.
569. Xin T, et al. In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current car-t cell therapy. Front Oncol 2022;12:809754.
570. Agarwalla P, et al. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells. Nat Biotechnol 2022.
571. Lorenzo-Herrero S, et al. NK cell-based immunotherapy in cancer metastasis. Cancers 2019;11:29.
572. Marofi F, et al. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Stem Cell Res Ther 2021;12:374.
573. Lupo KB, et al. Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy. Cancers 2019;11:769.
574. Nash AM, et al. Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors. Sci Adv 2022;8:eabm1032.
575. Wu Y, et al. Control of the activity of CAR-T cells within tumours via focused ultrasound. Nat Biomed Eng 2021;5:1336-47.
576. Angelici B, et al. An AAV gene therapy computes over multiple cellular inputs to enable precise targeting of multifocal hepatocellular carcinoma in mice. Sci Transl Med 2021;13:eabh4456.
577. Mao C, et al. Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression. Sci Transl Med 2022;14:eabh1261.
578. American Association for Cancer Research. Decades of cancer vaccine research enabled rapid development of COVID-19 vaccines. Accessed: June 30, 2022. Available from: https://www.aacr.org/blog/2021/02/08/decades-of-cancer-vaccine-research-enabled-rapid-development-of-covid-19-vaccines/
579. ClinicalTrials.Gov. Safety, tolerability, and immunogenicity of mRNA-4157 alone in participants with resected solid tumors and in combination with pembrolizumab in participants with unresectable solid tumors (KEYNOTE-603). Accessed: June 30, 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03313778
580. National Cancer Institute. How mRNA vaccines might help treat cancer. Accessed: June 30, 2022. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2022/mrna-vaccines-to-treat-cancer
581. Bai Y, et al. Liquid biopsy in tumors: opportunities and challenges. Ann Transl Med 2018;6:S89.
582. Tie J, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage ii colon cancer. N Engl J Med 2022;386:2261-72.
583. Madanat-Harjuoja LM, et al. Circulating tumor DNA as a biomarker in patients with stage III and IV wilms tumor: Analysis from a Children’s Oncology Group Trial, AREN0533. J Clin Oncol 2022:JCO2200098.
584. Cox A, et al. Chaperonin containing TCP1 as a marker for identification of circulating tumor cells in blood. PLoS One 2022;17:e0264651.
585. National Cancer Institute. Cancer screening research network/multi cancer early detection evaluation. Accessed: July 28, 2022. Available from: https://prevention.cancer.gov/sites/default/files/uploads/major_program/Cancer-Screening-Research-Network-MCED-20220615.pdf
586. Extramural Nexus. One nation in support of biomedical research? Accessed: July 14, 2022. Available from: https://www.ncbi.nlm.nih.gov/pubmed/
587. NIH Data Book. NIH Data Book – Success rates: R01-equivalent and research project grants. Accessed: July 14, 2022. Available from: https://www.ncbi.nlm.nih.gov/pubmed/
588. One Voice Against Cancer. More funding needed for CDC cancer programs. Accessed: July 14, 2022. Available from: http://www.ovaconline.org/wp-content/uploads/2022/04/OVAC-FY-23-CDC-Fact-Sheet.pdf
589. Reynolds AJ, et al. A multicomponent, preschool to third grade preventive intervention and educational attainment at 35 years of age. JAMA Pediatrics. Volume 172: American Medical Association; 2018. p 247-56.
590. National Institutes of Health. Science Education Partnership Award. Accessed: July 14, 2022. Available from: https://nihsepa.org/
591. The University of Arizone. Statistics & evaluation | Q-cubed. Accessed: July 28, 2022. Available from: https://ignorance.medicine.arizona.edu/programs/q-cubed
592. NCI Center to Reduce Cancer Health Disparities. National Cancer Institute’s (NCI’s) Continuing Umbrella of Research Experiences (CURE). Accessed: July 28, 2022. Available from: https://www.cancer.gov/about-nci/organization/crchd/diversity-training/cure
593. National Cancer Institute. NCI mentored research scientist development award to promote diversity (K01). Accessed: July 14, 2022. Available from: https://grants.nih.gov/grants/guide/pa-files/PAR-21-295.html
594. National Cancer Institute. Exploratory grant award to promote workforce diversity in basic cancer research (R21). Accessed: July 14, 2022.
595. NIH Extramural Nexus. What’s new with the NIH loan repayment programs: FY 2022 applications, anniversaries, and a new program. Accessed: July 14, 2022. Available from: https://www.ncbi.nlm.nih.gov/pubmed/
596. National Cancer Institute. NCI full year funding policy for RPG awards FY 2022. Accessed: July 14, 2022. Available from: https://www.ncbi.nlm.nih.gov/pubmed/
597. National Cancer Institute. MERIT Award (R37). Accessed: July 14, 2022. Available from: https://www.cancer.gov/grants-training/grants-funding/funding-opportunities/merit
598. Bleyer A, et al. Role of clinical trials in survival progress of American adolescents and young adults with cancer—and lack thereof. Pediatric Blood and Cancer 2018;65.
599. Hunger SP, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children’s oncology group. Journal of Clinical Oncology 2012;30.
600. Koo KC, et al. Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: A multi-center analysis. BMC Cancer 2018;18.

References 601-650

601. Unger JM, et al. “When offered to participate”: A systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. Journal of the National Cancer Institute. Volume 1132021.
602. Unger JM, et al. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. Journal of the National Cancer Institute. Volume 1112019.
603. Faulk KE, et al. Assessment of enrollment characteristics for Children’s Oncology Group (COG) upfront therapeutic clinical trials 2004-2015. PLoS ONE 2020;15.
604. Nipp RD, et al. Addressing the financial burden of cancer clinical trial participation: Longitudinal effects of an equity intervention. The Oncologist. Volume 24: Wiley; 2019. p 1048-55.
605. Valecha G, et al. Clinical trial awareness in oncology patients of diverse ethnic background: A single-institution analysis. Journal of Clinical Oncology. Volume 382020.
606. Institute of Medicine. Barriers to patient recruitment and physician participation. Accessed: June 30, 2022. Available from: https://www.ncbi.nlm.nih.gov/pubmed/
607. U.S. Food and Drug Administration. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials guidance for industry. Accessed: July 14, 2022. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations
608. Congress.Gov. H.R.6584 – 117th Congress (2021-2022): DEPICT Act. Accessed: June 30, 2022. Available from: https://www.congress.gov/bill/117th-congress/house-bill/6584/
609. Congress.Gov. S.2706 – 117th Congress (2021-2022): DIVERSE Trials Act. Accessed: June 30, 2022. Available from: https://www.congress.gov/bill/117th-congress/senate-bill/2706
610. National Cancer Institute. Risk Factors: Age. Accessed: August 12, 2022. Available from: https://www.cancer.gov/about-cancer/causes-prevention/risk/age
611. Ludmir EB, et al. Factors Associated With Age Disparities Among Cancer Clinical Trial Participants. JAMA Oncol 2019;5:1769-73.
612. U.S. Food and Drug Administration. Project Silver. Accessed: August 12, 2022. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/project-silver
613. U.S. Food and Drug Administration. Inclusion of Older Adults in Cancer Clinical Trials. Accessed: August 12, 2022. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inclusion-older-adults-cancer-clinical-trials
614. Tangka F, et al. The eligibility and reach of the national breast and cervical cancer early detection program after implementation of the affordable care act. Cancer Causes Control 2020;31:473-89.
615. LeBlanc JM, et al. Association of medicaid expansion under the affordable care act with breast cancer stage at diagnosis. JAMA Surg 2020;155:752-8.
616. Centers for Disease Control and Prevention. How many cancers are linked with HPV each year? Accessed: July 14, 2022. Available from: https://www.cdc.gov/cancer/hpv/statistics/cases.htm
617. National Conference of State Legislatures. HPV vaccine: State legislation and regulation. Accessed: July 14, 2022. Available from: https://www.ncsl.org/research/health/hpv-vaccine-state-legislation-and-statutes.aspx
618. Truth Initiative. E-cigarettes drive overall youth tobacco use to highest rate in decades. Accessed: July 15, 2022. Available from: https://truthinitiative.org/research-resources/emerging-tobacco-products/e-cigarettes-drive-overall-youth-tobacco-use-highest
619. U.S. Food and Drug Administration. Results from the annual national youth tobacco survey. Accessed: July 15, 2022. Available from: https://www.fda.gov/tobacco-products/youth-and-tobacco/results-annual-national-youth-tobacco-survey
620. Federal Register. Tobacco product standard for menthol in cigarettes. Accessed: July 15, 2022. Available from: https://www.federalregister.gov/documents/2022/05/04/2022-08994/tobacco-product-standard-for-menthol-in-cigarettes
621. Federal Register. Tobacco product standard for characterizing flavors in cigars. Accessed: July 15, 2022. Available from: https://www.federalregister.gov/documents/2022/05/04/2022-08993/tobacco-product-standard-for-characterizing-flavors-in-cigars
622. Villanti AC, et al. Menthol cigarettes and the public health standard: a systematic review. BMC Public Health 2017 17:1 2017;17:1-13.
623. Campaign for Tobacco-free Kids. Stopping menthol, saving lives. Accessed: July 15, 2022. Available from: https://www.tobaccofreekids.org/what-we-do/industry-watch/menthol-report
624. Levy DT, et al. Public health impact of a US ban on menthol in cigarettes and cigars: a simulation study. Tob Control 2021:tobaccocontrol-2021-056604.
625. U.S. Food and Drug Administration. FDA announces plans for proposed rule to reduce addictiveness of cigarettes and other combusted tobacco products. Accessed: July 15, 2022. Available from: https://www.fda.gov/news-events/press-announcements/fda-announces-plans-proposed-rule-reduce-addictiveness-cigarettes-and-other-combusted-tobacco
626. Apelberg BJ, et al. Potential public health effects of reducing nicotine levels in cigarettes in the united states. https://doiorg/101056/NEJMsr1714617. Volume 378: Massachusetts Medical Society; 2018. p 1725-33.
627. U.S. Food and Drug Administration. FDA issues decisions on additional e-Cigarette products. Accessed: July 15, 2022. Available from: https://www.fda.gov/news-events/press-announcements/fda-issues-decisions-additional-e-cigarette-products
628. U.S. Food and Drug Administration. FDA denies authorization to market JUUL products. Accessed: July 15, 2022. Available from: https://www.fda.gov/news-events/press-announcements/fda-denies-authorization-market-juul-products
629. Wang TW, et al. Tobacco product use and associated factors among middle and high school students – United States, 2019. MMWR Surveill Summ 2019;68:1-22.
630. technavio Blog. JUUL market share in 2019: Dominating the US e-cigarette market. Accessed: July 15, 2022. Available from: https://blog.technavio.org/blog/juul-market-share-dominating-e-cigarettes-market
631. National Cancer Institute. Molecular characterization initiative for childhood cancers. Accessed: July 15, 2022. Available from: https://www.cancer.gov/research/areas/childhood/childhood-cancer-data-initiative/molecular-characterization
632. U.S. Food and Drug Administration. Pediatric oncology. Accessed: July 15, 2022. Available from: https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology
633. U.S. Food and Drug Administration. Pediatric study plans: content of and process for submitting initial pediatric study plans and amended initial pediatric study plans. Accessed: July 15, 2022. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pediatric-study-plans-content-and-process-submitting-initial-pediatric-study-plans-and-amended
634. Medicaid.Gov. Federal Fiscal Year (FFY) 2020 Statistical Enrollment Data System (SEDS) reporting. Accessed: July 15, 2022. Available from: https://www.medicaid.gov/chip/downloads/fy-2020-childrens-enrollment-report.pdf
635. ChildStats.Gov. POP1 Child population: Number of children (in millions) ages 0-17 in the United States by age, 1950-2020 and projected 2021-2050. Accessed: July 15, 2022. Available from: https://www.childstats.gov/americaschildren/tables/pop1.asp
636. Pu CY, et al. Comparison between the 2021 USPSTF lung cancer screening criteria and other lung cancer screening criteria for racial disparity in eligibility. JAMA Oncol 2022;8:374-82.
637. General Assembly of North Carolina. House Bill 149. Accessed: July 15, 2022. Available from: https://www.ncleg.gov/BillLookUp/2021/h149
638. Kaiser Family Foundation. Status of state medicaid expansion decisions: Interactive map. Accessed: July 15, 2022. Available from: https://www.kff.org/medicaid/issue-brief/status-of-state-medicaid-expansion-decisions-interactive-map/
639. Su CT, et al. Affordable care act and cancer survivors’ financial barriers to care: Analysis of the national health interview survey, 2009-2018. JCO Oncology Practice2021.
640. Nathan NH, et al. Evaluating Medicaid expansion benefits for patients with cancer: National Cancer Database analysis and systematic review. J Cancer Policy 2021;29:100292.
641. Gany F, et al. Do our patients have enough to eat?: Food insecurity among urban low-income cancer patients. J Health Care Poor Underserved 2014;25:1153-68.
642. HealthyPeople.Gov. Food insecurity. Accessed: July 15, 2022. Available from: https://www.healthypeople.gov/2020/topics-objectives/topic/social-determinants-health/interventions-resources/food-insecurity
643. USDA Economic Research Services. Definitions of food security. Accessed: July 15, 2022. Available from: https://www.ers.usda.gov/topics/food-nutrition-assistance/food-security-in-the-u-s/definitions-of-food-security/
644. Centers for Disease Control and Prevention. Obesity and cancer. Accessed: July 15, 2022. Available from: https://www.cdc.gov/cancer/obesity/index.htm
645. Patel KG, et al. Food insecurity screening: A missing piece in cancer management. Cancer 2019;125:3494-501.
646. Centers for Disease Control and Prevention. Racial and ethnic approaches to community health. Accessed: July 15, 2022. Available from: https://www.cdc.gov/nccdphp/dnpao/state-local-programs/reach/
647. National Cancer Institute. The NCI Community Oncology Research Program (NCORP). Accessed: July 28, 2022. Available from: https://ncorp.cancer.gov/
648. National Institute of Minority Health and Health Disparities. Solicited and investigator-initiated research. Accessed: July 15, 2022. Available from: https://www.ncbi.nlm.nih.gov/pubmed/
649. Maani N, et al. COVID-19 and underinvestment in the public health infrastructure of the United States. Milbank Q 2020;98:250-9.
650. Kaiser Family Foundation. Hollowed-out public health system faces more cuts amid virus. Accessed: July 15, 2022. Available from: https://khn.org/news/us-public-health-system-underfunded-under-threat-faces-more-cuts-amid-covid-pandemic/

References 651-662

651. New York Times. ‘Small town, no hospital’: Covid-19 is overwhelming rural west Texas. Accessed: July 15, 2022. Available from: https://www.nytimes.com/2020/12/09/us/coronavirus-big-bend-marfa-rural-texas.html
652. Kaiser Family Foundation. States have yet to spend hundreds of millions of federal dollars to tackle covid health disparities. Accessed: July 15, 2022. Available from: https://khn.org/news/article/covid-health-disparities-federal-funding-state-spending/
653. Trust for America’s Health. The impact of chronic underfunding on America’s public health system: Trends, risks, and recommendations, 2021. Accessed: Dec 17, 2021. Available from: https://www.tfah.org/wp-content/uploads/2021/05/2021_PHFunding_Fnl.pdf
654. Fedewa SA, et al. Changes in cancer screening in the US during the COVID-19 pandemic. JAMA Netw Open 2022;5:e2215490.
655. Politico. Bad state data hides coronavirus threat as Trump pushes reopening. Accessed: July 15, 2022. Available from: https://www.politico.com/news/2020/05/27/bad-state-coronavirus-data-trump-reopening-286143
656. MedPage Today. Nursing homes shocked at ‘insanely wrong’ CMS data on COVID-19. Accessed: Nov 12, 2021. Available from: https://www.medpagetoday.com/infectiousdisease/covid19/86967
657. Kaiser Family Foundation. Faxes and snail mail: Will pandemic-era flaws unleash improved health technology? Accessed: July 15, 2022. Available from: https://khn.org/news/article/outdated-information-systems-infrastructure-pandemic-health-technology/
658. Centers for Disease Control and Prevention. Surveillance and data strategy: Notable milestones. Accessed: July 15, 2022. Available from: https://www.cdc.gov/surveillance/surveillance-data-strategies/milestones_2019-2020.html
659. Centers for Disease Control and Prevention. FY 2022 operating plan. Accessed: July 15, 2022. Available from: https://www.cdc.gov/budget/documents/fy2022/FY-2022-CDC-Operating-Plan.pdf
660. Broadband Now Research. Broadbandnow estimates availability for all 50 states; confirms that more than 42 million americans do not have access to broadband. Accessed: July 15, 2022. Available from: https://broadbandnow.com/research/fcc-broadband-overreporting-by-state
661. Universal Services Administrative Co. 2020 annual report. Accessed: July 15, 2022. Available from: https://www.usac.org/wp-content/uploads/about/documents/annual-reports/2021/2021_USAC_Annual_Report.pdf
662. U.S. Department of Commerce. Fact sheet: Department of Commerce’s use of bipartisan infrastructure deal funding to help close the digital divide. Accessed: July 15, 2022. Available from: https://www.commerce.gov/news/fact-sheets/2021/11/fact-sheet-department-commerces-use-bipartisan-infrastructure-deal-funding